147 related articles for article (PubMed ID: 30871330)
1. Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis.
Akioyamen LE; Tu JV; Genest J; Ko DT; Coutin AJS; Shan SD; Chu A
Angiology; 2019 Sep; 70(8):726-736. PubMed ID: 30871330
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
3. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
Barkas F; Elisaf M; Milionis H
Atherosclerosis; 2015 Nov; 243(1):60-4. PubMed ID: 26350916
[TBL] [Abstract][Full Text] [Related]
4. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
5. Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease.
Calling S; Ji J; Sundquist J; Sundquist K; Zöller B
Int J Cardiol; 2013 Oct; 168(3):2844-50. PubMed ID: 23642611
[TBL] [Abstract][Full Text] [Related]
6. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
7. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
[TBL] [Abstract][Full Text] [Related]
8. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia.
Kusters DM; Caceres M; Coll M; Cuffie C; Gagné C; Jacobson MS; Kwiterovich PO; Lee R; Lowe RS; Massaad R; McCrindle BW; Musliner TA; Triscari J; Kastelein JJ
J Pediatr; 2015 Jun; 166(6):1377-84.e1-3. PubMed ID: 25841542
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
11. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
12. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
Akioyamen LE; Genest J; Chu A; Inibhunu H; Ko DT; Tu JV
J Clin Lipidol; 2019; 13(1):15-30. PubMed ID: 30527766
[TBL] [Abstract][Full Text] [Related]
15. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
17. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study.
Emanuelsson F; Nordestgaard BG; Tybjærg-Hansen A; Benn M
J Am Coll Cardiol; 2019 Sep; 74(11):1465-1476. PubMed ID: 31514949
[TBL] [Abstract][Full Text] [Related]
18. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
[TBL] [Abstract][Full Text] [Related]
19. Reduced global longitudinal strain at rest and inadequate blood pressure response during exercise treadmill testing in male heterozygous familial hypercholesterolemia patients.
Vartela V; Armenis I; Leivadarou D; Toutouzas K; Makrilakis K; Athanassopoulos GD; Karatasakis G; Kolovou G; Mavrogeni S; Perrea D
Int J Cardiol Hypertens; 2021 Jun; 9():100083. PubMed ID: 34095810
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein A5 gene promoter region-1131T/C polymorphism is associated with risk of ischemic stroke and elevated triglyceride levels: a meta-analysis.
Pi Y; Zhang L; Yang Q; Li B; Guo L; Fang C; Gao C; Wang J; Xiang J; Li J
Cerebrovasc Dis; 2012; 33(6):558-65. PubMed ID: 22688093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
